Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target at $87.00

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has received a consensus rating of “Moderate Buy” from the fourteen analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $87.00.

A number of equities analysts recently issued reports on RARE shares. Guggenheim reiterated a “buy” rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Piper Sandler lowered their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a research report on Monday, March 17th. JPMorgan Chase & Co. upped their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. Morgan Stanley upped their price objective on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an “overweight” rating in a research report on Friday, May 9th. Finally, William Blair initiated coverage on shares of Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They set an “outperform” rating and a $65.00 target price on the stock.

Insider Activity at Ultragenyx Pharmaceutical

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company’s stock in a transaction on Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the sale, the director directly owned 15,344 shares of the company’s stock, valued at approximately $573,712.16. This represents a 13.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders have sold 3,167 shares of company stock valued at $118,824. Corporate insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company’s stock valued at $422,167,000 after purchasing an additional 89,389 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Ultragenyx Pharmaceutical by 28.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company’s stock valued at $116,559,000 after purchasing an additional 706,519 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Ultragenyx Pharmaceutical by 81.6% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company’s stock valued at $77,815,000 after purchasing an additional 965,919 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 0.3% in the 1st quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company’s stock valued at $74,419,000 after purchasing an additional 5,400 shares during the last quarter. Finally, Deutsche Bank AG boosted its stake in shares of Ultragenyx Pharmaceutical by 0.5% in the 1st quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company’s stock valued at $61,611,000 after purchasing an additional 8,385 shares during the last quarter. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Trading Down 0.7%

Shares of NASDAQ:RARE opened at $39.19 on Thursday. The firm has a 50 day moving average of $36.72 and a 200-day moving average of $39.01. The stock has a market capitalization of $3.71 billion, a PE ratio of -6.66 and a beta of 0.26. Ultragenyx Pharmaceutical has a 12 month low of $29.59 and a 12 month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.03). The company had revenue of $139.29 million for the quarter, compared to analyst estimates of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. Ultragenyx Pharmaceutical’s revenue for the quarter was up 28.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.03) earnings per share. On average, research analysts predict that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.